오하이오의 난소암 임상 시험
난소암 관련 연구 68개가 오하이오 내 여러 지역에서 참여자를 모집하고 있습니다.
오하이오의 도시
- Columbus연구 39개
- Cleveland연구 29개
- Cincinnati연구 18개
- Toledo연구 11개
- Dayton연구 8개
- Akron연구 6개
- Parma연구 4개
- Athens연구 3개
- Mansfield연구 3개
- Mentor연구 3개
- Marion연구 3개
공식 연구 텍스트(영어)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- OhioHealth O'Bleness Hospital, Athens
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- 외 41개
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05564377A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- University of Cincinnati Medical Center ( Site 0090), Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT06824467A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- University of Cincinnati Medical Center ( Site 0042), Cincinnati
- The Ohio State University ( Site 0005), Hilliard
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT07318558Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- OhioHealth O'Bleness Hospital, Athens
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Geauga Hospital, Chardon
- 외 26개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06580314A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0108, Columbus
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 9. 업데이트됨 · NCT07546500Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 6. 업데이트됨 · NCT07851025Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- The Ohio State University Comprehensive Cancer Center, Hilliard
피험자 모집 중2상
18세 이상 · 여성 · 2026. 11. 6. 업데이트됨 · NCT06787612A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Aultman Alliance Community Hospital, Alliance
- OhioHealth O'Bleness Hospital, Athens
- UHHS-Chagrin Highlands Medical Center, Beachwood
- 외 37개
피험자 모집 중
35세 ~ 50세 · 여성 · 2026. 11. 6. 업데이트됨 · NCT04251052The Vanguard Study: Testing a New Way to Screen for Cancer
- Louis Stokes Cleveland VA Medical Center, Cleveland
피험자 모집 중건강한 지원자 환영
45세 ~ 75세 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT06995898Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Cleveland Clinic Foundation, Cleveland
피험자 모집 중관찰 연구
18세 이상 · 여성 · 2026. 11. 5. 업데이트됨 · NCT05051722A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Miami Valley Hospital South, Centerville
- University of Cincinnati Medical Center, Cincinnati
- Oncology Hematology Care Inc, Cincinnati
- 외 7개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07213804Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06400472A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06760819FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- The Christ Hospital Physicians - Mt. Auburn, Cincinnati
- Ohio State University CRS, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06303505A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 30. 업데이트됨 · NCT05128825Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Cleveland Clinic Mercy Hospital, Canton
- University Hospitals Seidman Cancer Center, Cleveland
- Tri-County Hematology & Oncology Associates, Inc., Massillon
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT05974150A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT07109726Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Miami Valley Hospital South, Centerville
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 28. 업데이트됨 · NCT06819007Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
피험자 모집 중1/2상
18세 ~ 90세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06710756A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Ohio State University Wexner Medical Center, Hilliard
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06161025Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT04981119A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT04657068A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- 외 3개
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 20. 업데이트됨 · NCT06890338Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Research Site, Cleveland
- Research Site, Cleveland
- Research Site, Mayfield Heights
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 16. 업데이트됨 · NCT07816666A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 13. 업데이트됨 · NCT07059845Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The Ohio State University, Columbus
피험자 모집 중1상
15세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06276491Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Miami Valley Hospital South, Centerville
- Zangmeister Cancer Center, Columbus
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 6. 업데이트됨 · NCT07225270Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Columbus
피험자 모집 중1/2상
18세 ~ 130세 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
- University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
피험자 모집 중2상
18세 이상 · 여성 · 2026. 10. 1. 업데이트됨 · NCT07024784A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07814248Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 25. 업데이트됨 · NCT03564340DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- The Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 24. 업데이트됨 · NCT04590326Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
피험자 모집 중2상
18세 ~ 130세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05489211ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.